Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study.
Fiche publication
Date publication
août 2019
Journal
World journal of gastrointestinal oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FRAISSE Jean, Pr GHIRINGHELLI François, Dr VINCENT Julie, Dr BENGRINE-LEFEVRE Leila, Dr ORRY David, Dr HENNEQUIN Audrey
Tous les auteurs :
Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F
Lien Pubmed
Résumé
Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results.
Mots clés
Gastric cancer, Neoadjuvant chemotherapy, Retrospective study, TeFOX
Référence
World J Gastrointest Oncol. 2019 Aug 15;11(8):634-641